Kahn S E, Leonetti D L, Prigeon R L, Boyko E J, Bergstrom R W, Fujimoto W Y
Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, USA.
J Clin Endocrinol Metab. 1995 Apr;80(4):1399-406. doi: 10.1210/jcem.80.4.7714116.
Obesity is associated with noninsulin-dependent diabetes mellitus (NIDDM) and coronary heart disease (CHD), and these interactions have usually been related to changes in immunoreactive insulin (IRI) levels. A role of proinsulin (PI) in this association has been suggested. We, therefore, examined IRI, PI, and true insulin levels and the PI/IRI ratio by glucose tolerance or CHD status in a cross-sectional study of 170 Japanese-American men (45-74 yr old) in whom 2 measures of adiposity (body mass index and intraabdominal fat) were made to assess potential associations in this population with a high prevalence of both NIDDM and CHD. Subjects were classified as having normal glucose tolerance (n = 58), impaired glucose tolerance (IGT; n = 55), or NIDDM (n = 57) or were classified by CHD status (without CHD, n = 127; with CHD, n = 43). A positive linear relationship existed between obesity, determined either as the body mass index or intraabdominal fat, and IRI, PI, and true insulin, but not the PI/IRI ratio. In the NIDDM subjects, PI levels were disproportionately greater than those in subjects with normal glucose tolerance or IGT, so the PI/IRI ratio was significantly greater in the NIDDM group [mean (95% confidence interval): normal glucose tolerance, 11.8% (range, 10.4-13.5); IGT, 12.8% (range, 10.8-15.1); NIDDM, 19.2% (range, 15.4-24.0); P = 0.0002] even when adjusted for obesity (P = 0.0004). In subjects with CHD compared to subjects without CHD, IRI (P = 0.0026) and true insulin levels (P = 0.0043) were increased, but PI levels were not. However, these differences were not present after adjustment for obesity. In contrast, when intraabdominal fat was adjusted for IRI or true insulin, a significant effect of intraabdominal fat on CHD risk was maintained (P = 0.045 and P = 0.029, respectively), suggesting that another factor(s) associated with central obesity may be involved in CHD risk. Thus, in Japanese-American men, elevated PI and PI/IRI ratio are markers of B-cell dysfunction, and these are not the result of obesity. An elevated true insulin level is present in those with CHD, but this appears to be the result of obesity. In contrast, central adiposity confers an additional risk for CHD independent of insulin.
肥胖与非胰岛素依赖型糖尿病(NIDDM)和冠心病(CHD)相关,而这些相互关系通常与免疫反应性胰岛素(IRI)水平的变化有关。有人提出胰岛素原(PI)在这种关联中起作用。因此,在一项对170名日裔美国男性(45 - 74岁)的横断面研究中,我们根据葡萄糖耐量或冠心病状况检测了IRI、PI、真实胰岛素水平以及PI/IRI比值,并进行了两项肥胖指标(体重指数和腹部内脂肪)的测量,以评估在NIDDM和CHD患病率均较高的该人群中的潜在关联。受试者被分为葡萄糖耐量正常(n = 58)、葡萄糖耐量受损(IGT;n = 55)或NIDDM(n = 57),或者根据冠心病状况分类(无冠心病,n = 127;有冠心病,n = 43)。无论是以体重指数还是腹部内脂肪衡量的肥胖与IRI、PI和真实胰岛素之间存在正线性关系,但与PI/IRI比值无关。在NIDDM受试者中,PI水平比葡萄糖耐量正常或IGT的受试者高得不成比例,因此NIDDM组的PI/IRI比值显著更高[平均值(95%置信区间):葡萄糖耐量正常,11.8%(范围,10.4 - 13.5);IGT,12.8%(范围,10.8 - 15.1);NIDDM,19.2%(范围,15.4 - 24.0);P = 0.0002],即使在调整肥胖因素后(P = 0.0004)也是如此。与无冠心病的受试者相比,有冠心病的受试者中IRI(P = 0.0026)和真实胰岛素水平(P = 0.0043)升高,但PI水平未升高。然而,在调整肥胖因素后这些差异不复存在。相反,当根据IRI或真实胰岛素调整腹部内脂肪时,腹部内脂肪对冠心病风险的显著影响仍然存在(分别为P = 0.045和P = 0.029),这表明与中心性肥胖相关的另一个因素可能与冠心病风险有关。因此,在日裔美国男性中,PI和PI/IRI比值升高是B细胞功能障碍的标志,且这并非肥胖所致。冠心病患者存在真实胰岛素水平升高,但这似乎是肥胖的结果。相比之下,中心性肥胖赋予了独立于胰岛素之外的额外冠心病风险。